ICON Acquires Mapi Group
27 Juillet 2017 - 12:05PM
Business Wire
Expands ICON’s leadership in Health Outcomes
Research and Commercialisation Services
ICON plc, (NASDAQ:ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that
it has acquired the Mapi Group, a leading Patient-Centered Health
Outcomes Research and Commercialisation company.
The acquisition strengthens ICON’s existing Commercialisation
and Outcomes Research business adding significant commercialisation
presence, analytics, real world evidence generation and strategic
regulatory expertise. The combined organisation will be a leader
for real world evidence, post approval research, language services,
consultancy services supporting clinical outcomes assessments,
pricing and market access and scientific communications.
The acquisition also enables ICON to have direct access to Mapi
Research Trust, the industry’s most subscribed library of Clinical
Outcomes Assessments (COAs), with exclusive distribution of over
300 families of validated questionnaires, including licensing of
COA services used by commercial, academic and regulatory research
organisations.
"The late phase CRO market continues to grow as our customers
face greater scrutiny from regulators and reimbursement bodies
around real-world evidence of product value and safety,” commented
Dr. Steve Cutler, Chief Executive Officer, ICON plc. “The
acquisition of Mapi extends the breadth and depth of ICON’s late
phase capabilities, creating an industry leading provider of
post-approval research, spanning evidence generation, strategic
regulatory services, scientific communications and commercial
strategy. Our customers will also benefit from ICON’s access to the
industry’s broadest set of COA tools and instruments as well as new
and enhanced real world data sets. Mapi has been a pioneer of late
phase and outcomes research since their foundation and we are
delighted to welcome their team of experts to ICON.”
“By combining with ICON, our customers will have access to a
broader global footprint, additional depth of experience, new
scientific communication services and access to innovative
solutions to capture real world data from patients," commented
James Karis, CEO of Mapi Group. “In addition, our customers will
have access to a wide range of global clinical services, spanning
all phases of development. Mapi and ICON are an ideal combination,
having complimentary services and a shared mission to provide
superior research solutions that help improve the lives of patients
globally."
“I am delighted that Mapi will become part of ICON, a company
that has a similar culture and vision that will enable Mapi to
continue the focus on innovation that we have developed over the
last forty-three years,” commented Bernard Jambon, Mapi’s founder
and Chairman of the Board of Directors.
About Mapi Group
Mapi Group has over 40 years of experience supporting
Life-Science companies as the world leading Patient-Centered
Research company in commercializing novel treatments through
Real-World Evidence, Strategic Regulatory Services,
Pharmacovigilance, Market Access, Language Services. Mapi Group is
the premier provider of Health Research and Commercialization
services to Life-Science companies enabling Market Authorization,
Market Access and Market Adoption of novel therapeutics. Visit
http://www.mapigroup.com for more information.
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 84 locations in 38 countries and has approximately
12,300 employees.
Further information is available at www.iconplc.com
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-F
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170727005556/en/
Investor Relations, 1-888-381-7923orBrendan Brennan, + 353 1 291
2000Chief Financial OfficerorJonathan Curtain, +1-215-616-3000Vice
President Corporate Finance & Investor Relations
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024